Figure 1.

Study design. The training cohort and test cohort that contain data from patients with CT images and pathology slides were used to develop the radiomics signature of MRS. Two additional cohorts were used to validate the clinical and prognostic value of this radiomics signature. The surgical resection cohort comprised clinical data and the corresponding imaging data from patients with surgical resection. The immunotherapy cohort comprised advanced HCC patients who had been treated with anti-PD-1 or anti-PD-L1 therapy. MRS, myeloid response score.